Mrk Merck & Co Inc Firm Profile
With offices in 140 countries, we aim to make a real difference with an revolutionary range of services and pharmaceutical items which promote and help health and wellbeing. Beneath the terms of the agreement 4D’s proprietary MicroRx® platform will be paired with MSD’s knowledge in the development and commercialisation of novel vaccines, to discover and create LBPs as vaccines in up to 3 undisclosed indications. 4D has the suitable, subject to particular circumstances, to trigger MSD to buy $5 million in ordinary shares in 4D in the course of the initial 12 months of the collaboration. MSD will be responsible...